Transplantation pulmonaire et Hypertension pulmonaire
Transcription
Transplantation pulmonaire et Hypertension pulmonaire
26/09/2012 Colloque SSPH 2012 Transplantation pulmonaire et Hypertension pulmonaire JD Aubert, Service de Pneumologie Agenda • Transplantation pulmonaire pour l’h l’hypertension t i artérielle té i ll pulmonaire l i • Transplantation pulmonaire pour des pneumopathies chroniques compliquées par une hypertension pulmonaire • (Transplantation cardiaque en cas d’hypertension pulmonaire post capillaire « hors de proportion ») 1 26/09/2012 BREATHE-1: Analysis of survival Event-free (%) 100 Treatment 125/250 mg bid 75 Placebo 50 25 p < 0.05 at weeks 16 and 28 0 0 4 8 144 69 142 68 141 63 12 16 20 24 28 138 62 103 48 31 10 25 7 Patients at risk 13 Bosentan 3 Placebo Time (weeks) Rubin LJ, et al. N Engl J Med 2002; 346:896-903. 2 26/09/2012 ISHLT ISHLT BREATHE-1: Analysis of survival Event-free (%) 100 Treatment 125/250 mg bid 75 Placebo 50 25 p < 0.05 at weeks 16 and 28 0 0 4 8 144 69 142 68 141 63 12 16 20 24 28 138 62 103 48 31 10 25 7 Patients at risk 13 Bosentan 3 Placebo Time (weeks) Rubin LJ, et al. N Engl J Med 2002; 346:896-903. 3 26/09/2012 The impact of baseline FC on patient outcomes 100 p = 0.0001 0 0001 Survival (%) 80 FC I/II (n = 139) 60 FC III (n = 268) 40 FC IV (n = 77) ( ) 20 0 0 1 2 3 Time (years) 4 5 Kane G, et al. Chest 2011; 139:1285-93. 4 26/09/2012 5 26/09/2012 Problèmes péri-opératoires • Lésions d’ischémie-reperfusion du greffon • Défaillance cardiaque droite à l’induction • Défaillance cardiaque gauche après l’implantation (dysfonction diastolique) • Dysfonction d’autres organes: cirrhose cardiaque/médicamenteuse, di / édi t iinsuffisance ffi rénale…. 6 26/09/2012 Transplantation: Current recommendations (2008 consensus and 2009 ESC/ERS Guidelines) • Medical treatment is mandatory, but should not delay lung transplantation • Appropriate patients in FC IV must be referred • Appropriate patients with veno-occlusive disease or pulmonary capillary haemangiomatosis should be referred to a lung transplantation centre after diagnosis • Timing for transplantation will be influenced by waiting times, functional class, exercise capacity and treatment response Keogh AM, et al. J Am Coll Cardiol 2009; 54:S67-S77. Galiè N, et al. Eur Heart J 2009; 30:2493-537. 7 26/09/2012 8 26/09/2012 Validation of the REVEAL risk score: Long-term mortality in PAH The REVEAL score* was calculated for 484 PAH patients at baseline and was proportional to long-term mortality Survival (%) S 100 80 1 – 4 (n = 84) 60 5 – 6 (n = 140) 40 7 – 8 (n = 159) 20 0 ( ) 9 (n = 48) ≥ 10 (n = 53) p < 0.0001 0 1 2 3 4 Time (years) 5 Kane G, et al. Chest 2011; 139:1285-93. *Benza RL, et al. Circulation 2010; 122:164-72. 9 26/09/2012 10 26/09/2012 Stratégie opératoire • Un poumon ? • Deux poumons ? • Cœur-poumons ? 11 26/09/2012 12 26/09/2012 Centre Universitaire Romand de Transplantation DONNÉES É LOCALES 13 26/09/2012 Répartition des diagnostics 2003-2012. N= 141 COPD CF IPF PAH Other Centre Lausanne Genève de TX pulmonaire Centre Lausanne Genève de TX pulmonaire 14 26/09/2012 The Toronto experience 15 26/09/2012 Hypertension pulmonaire de catégorie 3 ou 5 et transplantation COPD patients with PH have reduced survival compared to those without PH 1 0.9 Survival rate 0.8 0.7 0.6 0.5 0.4 p < 0.001 0.3 02 0.2 No PH PH 0.1 0 24 48 72 96 120 144 168 Time (months) Minai O, et al. Chest 2010; 137:39S-51S. 16 26/09/2012 A1 fbalse 20 abstract stractt(text) Cystic Fibrosis and PH J Cardiovasc Surg (Torino). 2012 May 28. [Epub ahead of print] p ] Pulmonary hypertension is associated with higher mortality in cystic fibrosis patients awaiting lung transplantation. Venuta F, Tonelli F Tonelli AR, Anile M, Diso AR Anile M Diso D, De D De Giacomo T, Ruberto F, Russo E, Rolla M, Quattrucci S, Rendina EA, Li Phd N, Coloni GF. Source Department of Thoracic Surgery, La Sapienza University of Rome, Rome, Italy ‐ [email protected]. Sarcoidosis and PH Presse Med. 2012 Jun;41(6 Pt 2):e303‐16. Epub 2012 May 18. Pulmonary hypertension complicating sarcoidosis. Pulmonary hypertension complicating sarcoidosis Nunes H, Uzunhan Y, Freynet O, Humbert M, Brillet PY, Kambouchner M, Valeyre D. Source University Paris 13, UPRES EA 2363, Assistance publique‐Hôpitaux de Paris, Avicenne Hospital, Department of Pneumology, 93009 Bobigny, France. [email protected] “PH PH carries a poor prognosis in sarcoidosis carries a poor prognosis in sarcoidosis patients, with a significantly increased morbidity and mortality” 17 26/09/2012 Sarcoidosis and PH: data from the Swiss Registry N= 22 G. Verdi, 2012 SSPH International meeting, 27.09.12 Evaluation of pulmonary arterial pressure in lung transplant candidates: transthoracic echocardiography versus right heart catheterization Jesica Mazza Stalder, Fréderic Lador, Paola M. Soccal, John‐David Aubert Lausanne‐Geneva Lung Transplantation Centre, Switzerland Table 1. Patients characteristics Characteristics Mean age (years) Sex ( female/male) N=47 50.4 (22-66) 27/ 20 COPD 29 Cystic fibrosis 8 Pulmonary hypertension 4 ¾ Idiopathic 2 ¾ Thromboembolic 1 ¾ Sarcoidosis 1 Others 8 Single lung transplant 9 Double lung transplant 38 18 26/09/2012 Table 2. Mortality in absence vs presence PHT Right heart catheter n=20 < or = 25 mmHg Right heart catheter n=25 >25 mmHg Mortality at 30 days 1/20 1/25 NS Mortality at 1 year 1/20 2/25 NS 600 6-MWT metres sPAP - RHC mmHg 60 40 20 0 400 200 0 No tricuspid jet evaluable 0 25 50 75 100 125 sPAP - RHC 19 26/09/2012 IMPACT DE L’HYPERTENSION PULMONAIRE SUR L’ALLOCATION DES ORGANES ABM SOAS LAS 3.6 7.01 4.5 TTemps moyen en 135 liste (j) 2082 148 % décès en liste 10.3 10.02 14 % poumons acceptés 17 422 36 HTAP cat 1 À la discrétion du transplanteur Priorité de niveau 3 +3.6 points * HTP cat 3/5 idem Priorité de niveau 3 si NYHA > III sous ttt + 0.55 points * Nb LTX/10E6 Comparé à BPCO sans HTAP 20 26/09/2012 Pour conclure • La transplantation pulmonaire est une option ti pour les l patients ti t avec HTAP ne répondant pas au traitement médical • L’HTP compliquant une pneumopathie chronique en aggrave le pronostic • Ces patients doivent être référés suffisamment tôt à un centre de transplantation 21